Hercules Capital, Inc. (HTGC)

NYQ – Real Time Price. Currency in USD

15.58

+0.34 (2.23%)

At close: Jun 26, 2026, 4:00 PM EDT

15.60

+0.02 (0.13%)

After-hours: Jun 26, 2026, 7:51 PM EDT

17.06.2026

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets.

16.06.2026

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Hercules Capital (HTGC) closed the most recent trading day at $15.65, moving +1.03% from the previous trading session.

10.06.2026

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., the parent company of Mandos LLC and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced it has secured $300 million in combined financing. The financing includes a $135 million equity financing alongside up to $165 million in a strategic financing facility with Hercules Capital, Inc. (NYSE: HTGC) across a senior secured debt and royalty structure. Capital will support Beren's growth.

09.06.2026

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital is a strong buy, trading at a rare 28.4% NAV premium versus its 5-year average of 49.36%. HTGC offers a 12.3% dividend yield, with distributions well covered by net investment income and supported by $149.1M in spillover income. The portfolio is conservatively structured, with 98% floating-rate senior secured loans and non-accruals at just 0.1% of fair value.

04.06.2026

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

Hercules Capital (HTGC) reported earnings 30 days ago. What's next for the stock?

27.05.2026

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

April net investment activity reached a multi-year low as rising stock valuations and BDC sector weakness prompted a cautious approach and selective BDC purchases. Focused April allocations on Ares Capital, Blue Owl Capital, and Hercules Capital, yielding a 7.5% average on new investments despite sector headwinds. Dividend income set a modest April record at $990, up 3% year-over-year, with BDCs contributing 27% of Q2 year-to-date dividends but facing potential further cuts.

24.05.2026

The High-Yield Stocks the Smart Money Is Buying Right Now

There is a principle I have followed for 30 years in this business. When the smartest credit team on the planet starts aggressively buying a beaten-down asset class they understand better than anyone alive, you do not sit on your hands and debate whether the timing is perfect.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
HTGC	Piper Sandler	Neutral	undefined >> $18	February 13th 2026

Press releases

17.06.2026

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

10.06.2026

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

20.05.2026

HTGC DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action - HTGC

New York, New York--(Newsfile Corp. - May 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hercules Capital, Inc. (NYSE: HTGC) between May 1, 2025 and February 27, 2026, inclusive (the "Class Period"), of the important May 19, 2026 lead plaintiff deadline. SO WHAT: If you purchased Hercules Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

19.05.2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hercules Capital, Inc. of Class Action Lawsuit and Upcoming Deadlines – HTGC

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hercules Capital, Inc. (“Hercules” or the “Company”) (NYSE: HTGC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Hercules Capital, Inc. (HTGC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Hercules Capital, Inc. (HTGC)

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

The High-Yield Stocks the Smart Money Is Buying Right Now

Videos

No Data

Upgrades / Downgrades

Press releases

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

HTGC DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action - HTGC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hercules Capital, Inc. of Class Action Lawsuit and Upcoming Deadlines – HTGC

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

The High-Yield Stocks the Smart Money Is Buying Right Now

Videos

No Data

Upgrades / Downgrades

Press releases

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

HTGC DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action - HTGC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hercules Capital, Inc. of Class Action Lawsuit and Upcoming Deadlines – HTGC

Search stocks

Hercules Capital, Inc. (HTGC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Hercules Capital, Inc. (HTGC)

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

The High-Yield Stocks the Smart Money Is Buying Right Now

Videos

No Data

Upgrades / Downgrades

Press releases

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

HTGC DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action - HTGC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hercules Capital, Inc. of Class Action Lawsuit and Upcoming Deadlines – HTGC

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Hercules Capital (HTGC) Ascends While Market Falls: Some Facts to Note

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

Hercules Capital: Attractive Valuation And Growth Potential

Hercules Capital (HTGC) Down 7.4% Since Last Earnings Report: Can It Rebound?

My Dividend Stock Portfolio: New April Dividend Record - 100 Holdings With 5 Buys

The High-Yield Stocks the Smart Money Is Buying Right Now

Videos

No Data

Upgrades / Downgrades

Press releases

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

HTGC DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action - HTGC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hercules Capital, Inc. of Class Action Lawsuit and Upcoming Deadlines – HTGC